glp 1 non responders Identifying Your Response to GLP-1 Medicines: Responder, Responder, or Hyper Responder Why GLP-1 Non-Responders Need Earlier

The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists

In this scenario, preventing excess glucagon secretion helps lower blood sugar levels

With SELECT trials outcome, even primary prevention cardiology (using Wegovy to prevent second heart attacks in obese patients) will become an accepted practice likely

Research published in the National Library of Medicine shows that semaglutide-based treatments produced meaningful weight reductions in adults with obesity or weight-related conditions

The approved dose of Wegovy is 2.4 mg, so doses of 1.7mg should be flagged for evaluation

The emerging thinking among those working in this field, and reflected in a statement by the Endocrine Society, is that obesity is due to two related but distinct processes: the already mentioned energy imbalance (eating more calories than the body expends) and the resetting of the body weight set point the weight that the body determines as its goal to a higher value